Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
329.60
16.80(3.98%)
At close: 4:00 PM EDT
329.60
16.80(3.98%)
Day’s Range― - ―
52-Week Range209.20 - 465.90
Previous CloseN/A
Volume19.47K
Average Volume (3M)5.53K
Market Cap
₪27.20M
Enterprise Value25.31M
Total Cash (Recent Filing)₪16.19M
Total Debt (Recent Filing)₪1.06M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,079,270
10 Day Avg. Volume4,853
30 Day Avg. Volume5,534
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage limits refinancing pressure and reduces the risk that interest obligations constrain operations. This provides some financial flexibility to preserve capital and support the business through periods of weak commercialization, despite the company’s ongoing losses.
Clinical-Care Market FocusBiolight operates in medical devices tied to patient monitoring and clinical care, where products serve essential healthcare workflows. This focus can support durable demand relevance if the company converts its technical offering into meaningful adoption by healthcare providers.
Broader Product PortfolioA portfolio spanning monitors, accessories, and related solutions gives Biolight multiple ways to address clinical customers rather than relying on one standalone device. A broader offering may support customer relationships and recurring product opportunities as adoption develops.
Bears Say
Minimal And Volatile RevenueRevenue that remains extremely small and has fallen to zero indicates that Biolight has not yet demonstrated a reliable commercial engine. Without consistent sales growth, the company may struggle to absorb its fixed cost base or establish durable operating scale over the coming quarters.
Persistent Operating LossesRecurring operating and net losses show that the current business model is not covering its cost structure. Continued losses reduce internal funding capacity, increase dependence on financing, and make sustained investment in product development or commercialization more difficult.
Ongoing Cash BurnPersistent operating and free-cash-flow deficits mean reported losses are translating into substantial cash outflows rather than mainly non-cash charges. Continued burn can erode financial resources and leave the company dependent on external funding to sustain operations.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 465.90 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪27.20M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 158 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Aug 24, 2026. The company reported -35.6 earnings per share for the quarter.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -35.6 in its last earnings report. Following the earnings report the stock price went up 1.185%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.